Portola Pharmaceuticals (NASDAQ:PTLA) is set to announce its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) EPS for the quarter, hitting the Zacks’ consensus estimate of ($1.02). The firm had revenue of $22.17 million during the quarter, compared to the consensus estimate of $20.60 million. Portola Pharmaceuticals had a negative return on equity of 238.48% and a negative net margin of 618.46%. The firm’s revenue was up 233.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.28) EPS. On average, analysts expect Portola Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of PTLA opened at $25.43 on Tuesday. The company has a market cap of $1.73 billion, a P/E ratio of -5.08 and a beta of 2.18. The stock’s fifty day moving average is $26.43. The company has a debt-to-equity ratio of 5.15, a quick ratio of 4.77 and a current ratio of 4.81. Portola Pharmaceuticals has a 12 month low of $14.81 and a 12 month high of $38.53.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Further Reading: How Does the Quiet Period Work?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.